Plant Based Protein Expression Market by Type of Product (Biosimilars, Cell Therapies, Gene Therapies, Monoclonal Antibodies, Vaccines and Others), Type of Plant (Algae, Barley, Benth, Duckweed, Lettuce, Maize, Moss, Rice, Tomato, Tobacco and Wheat Germ), Type of Expression System (Stable Expression System and Transient Expression System), Type of Target Disease Indication (Cirrhotic Ascites, COVID-19, Cystic Fibrosis, Ebola Virus Infection, Fabry Disease, Gaucher Disease, Liver Cirrhosis, Influenza, and Peanut Allergy), Type of Therapeutic Area (Genetic Disorders, Infectious Disorders, Liver Disorders, Respiratory Disorders and Others), Drug (Elelyso, PALFORZIA, OsrHSA, PRX-102, Unnamed_1, Unnamed_2, PRX-110 and ZMapp), and Region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2022-2035
The plant based protein expression market is expected to reach USD 1.3 billion in 2022 anticipated to grow at a CAGR of 11.9% during the forecast period 2022-2035.
The increasing preference for biologics has experienced a significant surge, particularly in the wake of the COVID-19 pandemic. Presently, approximately 85% of drug candidates are formulated using mammalian cell cultures, facing several challenges such as pathogen introduction, scalability limitations, reduced productivity, and increased byproduct formation. Studies indicate that the current capacities of mammalian cell production might only meet 50% of the heightened demand for biologics resulting from the COVID-19 crisis.
Amid these challenges, advancements in synthetic organic chemistry have shed light on plant-based expression systems as a promising alternative. The engineering of plant hosts enables the production of proteins with consistent post-translational modifications, resulting in more effective biologics compared to those derived from mammalian or yeast-based cultures. Plant-based systems also offer increased safety by posing minimal risks of introducing human or animal pathogens. Furthermore, plant molecular farming facilitates rapid and large-scale production (several grams) of biologics within a shorter timeframe (4-8 weeks), particularly evident during the COVID-19 pandemic. Additionally, Good Manufacturing Practice (GMP) plant-based manufacturing facilities report lower operating costs (approximately 25% less) compared to other expression systems.
Pharmaceutical entities are actively embracing plant-based systems due to these advantageous features. These systems have enabled the development of various therapeutics, vaccines, enzymes, monoclonal antibodies, and nutritional proteins using transgenic or transient expression in plants or plant cell cultures. Currently, nearly 50 plant-based therapies are undergoing development or evaluation, with over 35 providers offering proprietary technologies to drug developers. The industry is witnessing numerous partnerships among various stakeholders to further advance plant-based therapies, driven by factors such as disease prevalence, escalating demand for biologics, and ongoing optimization endeavors.
Considering the rising prevalence of diseases, increasing demand for biologics, continuous advancements in product development, and the ongoing optimization of technology, the global plant-based protein expression market is poised for substantial growth in the forecast period.
Report Coverage
The increasing preference for biologics has experienced a significant surge, particularly in the wake of the COVID-19 pandemic. Presently, approximately 85% of drug candidates are formulated using mammalian cell cultures, facing several challenges such as pathogen introduction, scalability limitations, reduced productivity, and increased byproduct formation. Studies indicate that the current capacities of mammalian cell production might only meet 50% of the heightened demand for biologics resulting from the COVID-19 crisis.
Amid these challenges, advancements in synthetic organic chemistry have shed light on plant-based expression systems as a promising alternative. The engineering of plant hosts enables the production of proteins with consistent post-translational modifications, resulting in more effective biologics compared to those derived from mammalian or yeast-based cultures. Plant-based systems also offer increased safety by posing minimal risks of introducing human or animal pathogens. Furthermore, plant molecular farming facilitates rapid and large-scale production (several grams) of biologics within a shorter timeframe (4-8 weeks), particularly evident during the COVID-19 pandemic. Additionally, Good Manufacturing Practice (GMP) plant-based manufacturing facilities report lower operating costs (approximately 25% less) compared to other expression systems.
Pharmaceutical entities are actively embracing plant-based systems due to these advantageous features. These systems have enabled the development of various therapeutics, vaccines, enzymes, monoclonal antibodies, and nutritional proteins using transgenic or transient expression in plants or plant cell cultures. Currently, nearly 50 plant-based therapies are undergoing development or evaluation, with over 35 providers offering proprietary technologies to drug developers. The industry is witnessing numerous partnerships among various stakeholders to further advance plant-based therapies, driven by factors such as disease prevalence, escalating demand for biologics, and ongoing optimization endeavors.
Considering the rising prevalence of diseases, increasing demand for biologics, continuous advancements in product development, and the ongoing optimization of technology, the global plant-based protein expression market is poised for substantial growth in the forecast period.
Report Coverage
- Executive summary includes the research insights about the current state and future evolution of the plant-based biologics and expression systems market.
- Introduction to the key concepts regarding plant-based expression system providers, including classifications, advantages, commonly used production systems, mechanisms, and recent developments.
- A detailed analysis of over 35 plant-based expression system providers, covering market landscape, types of plants used, products, expression systems, developer details, and proprietary technologies.
- A detailed analysis of more than 45 plant-based biologics, including their market landscape, development status, disease indications, therapeutic areas, types of products, developer landscape, and proprietary drug candidates.
- Detailed profiles of leading companies involved in plant-based expression system technologies, covering company overviews, technology portfolios, recent developments, and future outlooks.
- Recent collaborations and partnerships among stakeholders in the domain, covering various agreements and alliances from 2017-2021.
- A company competitiveness analysis using a matrix and spider web representation, comparing key players in plant-based expression systems based on parameters like experience, portfolio strength, partnership activity, and company size.
- Analysis of over 1,000 scientific articles related to plant-based biologics published between 2000-2021, highlighting research focus, trends, parameters like publication year, article types, journals, funding bodies, publishers, and authors.
- A detailed market forecast analysis for the plant-based expression system market from 2022-2035, including market size, growth potential, distribution of opportunities based on product type, plant type, expression system, and region.
- A detailed market forecast analysis for the plant-based biologics market from 2022-2035, including market size, growth potential, distribution of opportunities based on disease indications, therapeutic areas, specific drugs, and regions.
- Executive insights from discussions with various key stakeholders in this market.
- Medicago
- Leaf Expression Systems
- Eleva
- iBIO
- PlantForm
- G+Flas Life Sciences
- Kentucky Bioprocessing
- Angany
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Plant-based Biologics and Expression Systems
3.2. Classification of Plant-based Expression Platforms
3.3. Mechanism of Plant Expression Platform
3.4. Advantages Offered by Plant-based Bioproduction Systems
3.5. Commonly used Plant-based Bioproduction Systems
3.6. Key Developments
3.7. Future Perspectives
4. PLANT-BASED EXPRESSION SYSTEMS: MARKET LANDSCAPE
4.1. Plant-based Expression Systems: Market Overview and Developer Landscape
4.2. List of Plant-based Expression System Providers
4.2.1. Analysis by Type of Plant
4.2.2. Analysis by Type of Biologic
4.2.3. Analysis by Type of Plant and Type of Biologic
4.2.4. Analysis by Type of Biologic and Region
4.2.5. Analysis by Type of Plant, Type of Biologic and Region
4.2.6. Analysis by Type of Service
4.2.7. Analysis by Year of Establishment
4.2.8. Analysis by Company Size
4.2.9. Analysis by Region (Country-wise)
4.2.10. Analysis by Region (Continent-wise)
5. PLANT-BASED BIOLOGICS: MARKET LANDSCAPE
5.1. Plant-based Biologics: Pipeline Review and Developer Landscape
5.2. List of Drug Candidates
5.2.1. Analysis by Status of Development
5.2.2. Analysis by Target Disease Indication
5.2.3. Analysis by Therapeutic Area
5.2.4. Analysis by Status of Development and Therapeutic Area
5.2.5. Analysis by Type of Biologic
5.2.6. Analysis by Status of Development and Type of Product
5.3. Plant-based Biologics: List of Drug Developers
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Region
5.3.3.1. Analysis of Players in North America
5.3.3.2. Analysis of Players in Europe
5.3.3.3. Analysis of Players in Asia and Rest of the World
6. COMPANY PROFILES
6.1. Medicago
6.1.1. Company Overview
6.1.2. Technology Portfolio
6.2.3. Recent Developments and Future Outlook
6.2. Leaf Expression Systems
6.2.1. Company Overview
6.2.2. Technology Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Eleva
6.3.1. Company Overview
6.3.2. Technology Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. iBIO
6.4.1. Company Overview
6.4.2. Technology Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. PlantForm
6.5.1. Company Overview
6.5.2. Technology Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. G+Flas Life Sciences
6.6.1. Company Overview
6.6.2. Technology Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Kentucky Bioprocessing
6.7.1. Company Overview
6.7.2. Technology Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Angany
6.8.1. Company Overview
6.8.2. Technology Portfolio
6.8.3. Recent Developments and Future Outlook
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Plant-based Biologics and Expression Systems: Partnerships and Collaborations
7.1.1. Analysis by Cumulative Year-wise Trend of Partnerships
7.1.2. Analysis by Type of Partnership
7.1.3. Analysis by Year and Type of Partnership
7.1.4. Analysis by Type of Biologic
7.1.5. Analysis by Type of Partnership and Type of Biologic
7.1.6. Key Players: Analysis by Number of Partnerships
7.1.7. Analysis by Partner Headquarters (Region)
7.1.8. Analysis by Region and Type of Agreement
7.1.9. Intercontinental and Intracontinental Partnerships
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Plant-based Expression System Providers: Company Competitiveness Analysis
8.1.1. Assumptions and Key Parameters
8.1.2. Methodology
8.3. Benchmarking of Portfolio Strength
8.4. Benchmarking of Partnership Strength
8.5. Company Competitiveness Analysis: Small Companies
8.6. Company Competitiveness Analysis: Mid-sized Companies
8.7. Company Competitiveness Analysis: Large Companies
9. PUBLICATIONS ANALYSIS
9.1. Plant-based Biologics and Expression Systems: Publications Analysis
9.1.1. Analysis Methodology
9.1.2. Key Parameters
9.2. Analysis by Year of Publication
9.3. Analysis by Type of Publication
9.4. Key Journals based on Publications Count
9.5. Analysis by Primary Author
9.6. Analysis by Publisher
9.7. Analysis by Primary Funding Body
9.8. Analysis by Journal Impact Factor
9.9. Analysis by Key Journals and Journal Impact Factor
9.10. Word Cloud: Emerging Focus Area
9.11. Timeline Analysis
9.11.1. Analysis by Article Type and Timeline of Receipt, Acceptance and ApprovalAnalysis by Article Type and Timeline of Receipt, Acceptance and Approval
9.11.2. Analysis by Journal Impact Factor and Timeline of Receipt, Acceptance and ApprovalAnalysis by Journal Impact Factor and Timeline of Receipt, Acceptance and Approval
9.11.3. Analysis by Grant Awarded and Timeline of Receipt, Acceptance and Approval
9.12. Benchmarking Methodology
9.13. Benchmarking Analysis
9.14. List of Top 50 Publications
10. PLANT-BASED EXPRESSION SYSTEMS: MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Methodology and Key Assumptions
10.2. Segments Forecasted
10.3. Plant-based Expression Systems: Sales Forecast
10.4. Analysis by Type of Product: Global Sales Forecast, 2022 and 2035
10.4.1. Plant-based Expression Systems Market for Biosimilars, 2022-2035
10.4.2. Plant-based Expression Systems Market for Cell Therapies, 2022-2035
10.4.3. Plant-based Expression Systems Market for Gene Therapies, 2022-2035
10.4.4. Plant-based Expression Systems Market for Monoclonal Antibodies, 2022-2035
10.4.5. Plant-based Expression Systems Market for Vaccines, 2022-2035
10.4.6. Plant-based Expression Systems Market for Others, 2022-2035
10.5. Distribution by Type of Plant: Global Sales Forecast, 2022 and 2035
10.5.1. Plant-based Expression Systems Market for Algae, 2022-2035
10.5.2. Plant-based Expression Systems Market for Barley, 2022-2035
10.5.3. Plant-based Expression Systems Market for Benth, 2022-2035
10.5.4. Plant-based Expression Systems Market for Duckweed, 2022-2035
10.5.5. Plant-based Expression Systems Market for Lettuce, 2022-2035
10.5.6. Plant-based Expression Systems Market for Maize, 2022-2035
10.5.7. Plant-based Expression Systems Market for Moss, 2022-2035
10.5.8. Plant-based Expression Systems Market for Rice, 2022-2035
10.5.9. Plant-based Expression Systems Market for Tomato, 2022-2035
10.5.10. Plant-based Expression Systems Market for Tobacco, 2022-2035
10.5.11. Plant-based Expression Systems Market for Wheat Germ, 2022-2035
10.6. Analysis by Type of Expression System: Global Sales Forecast, 2022 and 2035
10.6.1. Plant-based Expression Systems Market for Stable Expression System, 2022-2035
10.6.2. Plant-based Expression Systems Market for Transient Expression System,2022-2035
10.7. Analysis by Region: Global Sales Forecast, 2022 and 2035
10.7.1. Plant-based Expression Systems Market in North America, 2022-2035
10.7.2. Plant-based Expression Systems Market in Europe, 2022-2035
10.7.3. Plant-based Expression Systems Market in Asia, 2022-2035
10.7.4. Plant-based Expression Systems Market in Latin America, 2022-2035
10.7.5. Plant-based Expression Systems Market in MENA, 2022-2035
10.7.6. Plant-based Expression Systems Market in Rest of the World, 2022-2035
11. PLANT-BASED BIOLOGICS: MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. List of Forecasted DrugsKey Parameters and Assumptions
11.2. List of Forecasted DrugsAnalysis Methodology
11.3. List of Forecasted Drugs
11.3.1. Elelyso, Protalix Biotherapeutics
11.3.1.1. Global Sales Forecast
11.3.1.2. Regional Sales Forecast
11.3.1.3. Net Present Value
11.3.1.4. Value Creation Analysis
11.3.2. PALFORZIA, Aimmune Therapeutics
11.3.2.1. Global Sales Forecast
11.3.2.2. Regional Sales Forecast
11.3.2.3. Net Present Value
11.3.2.4. Value Creation Analysis
11.3.3. OsrHSA, Healthgen Biotechnology
11.3.3.1. Global Sales Forecast
11.3.3.2. Regional Sales Forecast
11.3.3.3. Net Present Value
11.3.3.4. Value Creation Analysis
11.3.4. PRX-102, Protalix Biotherapeutics
11.3.4.1. Global Sales Forecast
11.3.4.2. Regional Sales Forecast
11.3.4.3. Net Present Value
11.3.4.4. Value Creation Analysis
11.3.5. Unnamed_1, Medicago
11.3.5.1. Global Sales Forecast
11.3.5.2. Regional Sales Forecast
11.3.5.3. Net Present Value
11.3.5.4. Value Creation Analysis
11.3.6. Unnamed_2, Medicago
11.3.6.1. Global Sales Forecast
11.3.6.2. Regional Sales Forecast
11.3.6.3. Net Present Value
11.3.7.4. Value Creation Analysis
11.3.7. PRX-110, Protalix Biotherapeutics
11.3.7.1. Global Sales Forecast
11.3.7.2. Regional Sales Forecast
11.3.7.3. Net Present Value
11.3.7.4. Value Creation Analysis
11.3.8. ZMapp, Mapp Biopharmaceutical
11.3.8.1. Global Sales Forecast
11.3.8.2. Regional Sales Forecast
11.3.8.3. Net Present Value
11.3.8.4. Value Creation Analysis
11.4. Global Plant-based Biologics Market: Analysis by Target Disease Indication, 2022 and 2035
11.4.1. Plant-based Biologics Market for Cirrhotic Ascites, 2022-2035
11.4.2. Plant-based Biologics Market for COVID-19, 2022-2035
11.4.3 Plant-based Biologics Market for Cystic Fibrosis, 2022-2035
11.4.4 Plant-based Biologics Market for Ebola Virus Infection, 2022-2035
11.4.5. Plant-based Biologics Market for Fabry Disease, 2022-2035
11.4.6. Plant-based Biologics Market for Gaucher Disease, 2022-2035
11.4.7. Plant-based Biologics Market for Influenza, 2022-2035
11.4.8. Plant-based Biologics Market for Liver Cirrhosis, 2022-2035
11.4.9. Plant-based Biologics Market for Peanut Allergy, 2022-2035
11.5. Plant-based Biologics Market: Analysis by Therapeutic Area, 2022 and 2035
11.5.1. Plant-based Biologics Market for Genetic Disorders, 2022-2035
11.5.2 Plant-based Biologics Market for Infectious Disorders, 2022-2035
11.5.3 Plant-based Biologics Market for Liver Disorders, 2022-2035
11.5.4. Plant-based Biologics Market for Respiratory Disorders, 2022-2035
11.5.5. Plant-based Biologics Market for Others, 2022-2035
11.6. Plant-based Biologics Market: Analysis by Region, 2022 and 2035
11.6.1. Plant-based Biologics Market in North America, 2022-2035
11.6.2. Plant-based Biologics Market in Europe, 2022-2035
11.6.3. Plant-based Biologics Market in Asia, 2022-2035
11.6.4. Plant-based Biologics Market in Rest of the World, 2022-2035
11.7. Plant-based Biologics: Overall Market Opportunity, 2022-2035
11.8. Plant-based Biologics: Market Share of Key Players
11.9. Plant-based Biologics: Regional Distribution, 2022,2028 and 2035
11.10. Region-wise Distribution (Bubble Chart Representation)
12. EXECUTIVE INSIGHTS
12.1. Transactiva
12.1.1. Company Snapshot
12.1.2. Interview Transcript: Sara Raccovelli (Researcher)
12.2. ORF Genetics
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Jъlнus B Kristinsson (Chief Project Manager, Business Development & Co-Founder)
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 1: PUBLICATIONS DATA
15. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Plant-based Biologics and Expression Systems
3.2. Classification of Plant-based Expression Platforms
3.3. Mechanism of Plant Expression Platform
3.4. Advantages Offered by Plant-based Bioproduction Systems
3.5. Commonly used Plant-based Bioproduction Systems
3.6. Key Developments
3.7. Future Perspectives
4. PLANT-BASED EXPRESSION SYSTEMS: MARKET LANDSCAPE
4.1. Plant-based Expression Systems: Market Overview and Developer Landscape
4.2. List of Plant-based Expression System Providers
4.2.1. Analysis by Type of Plant
4.2.2. Analysis by Type of Biologic
4.2.3. Analysis by Type of Plant and Type of Biologic
4.2.4. Analysis by Type of Biologic and Region
4.2.5. Analysis by Type of Plant, Type of Biologic and Region
4.2.6. Analysis by Type of Service
4.2.7. Analysis by Year of Establishment
4.2.8. Analysis by Company Size
4.2.9. Analysis by Region (Country-wise)
4.2.10. Analysis by Region (Continent-wise)
5. PLANT-BASED BIOLOGICS: MARKET LANDSCAPE
5.1. Plant-based Biologics: Pipeline Review and Developer Landscape
5.2. List of Drug Candidates
5.2.1. Analysis by Status of Development
5.2.2. Analysis by Target Disease Indication
5.2.3. Analysis by Therapeutic Area
5.2.4. Analysis by Status of Development and Therapeutic Area
5.2.5. Analysis by Type of Biologic
5.2.6. Analysis by Status of Development and Type of Product
5.3. Plant-based Biologics: List of Drug Developers
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Region
5.3.3.1. Analysis of Players in North America
5.3.3.2. Analysis of Players in Europe
5.3.3.3. Analysis of Players in Asia and Rest of the World
6. COMPANY PROFILES
6.1. Medicago
6.1.1. Company Overview
6.1.2. Technology Portfolio
6.2.3. Recent Developments and Future Outlook
6.2. Leaf Expression Systems
6.2.1. Company Overview
6.2.2. Technology Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Eleva
6.3.1. Company Overview
6.3.2. Technology Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. iBIO
6.4.1. Company Overview
6.4.2. Technology Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. PlantForm
6.5.1. Company Overview
6.5.2. Technology Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. G+Flas Life Sciences
6.6.1. Company Overview
6.6.2. Technology Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Kentucky Bioprocessing
6.7.1. Company Overview
6.7.2. Technology Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Angany
6.8.1. Company Overview
6.8.2. Technology Portfolio
6.8.3. Recent Developments and Future Outlook
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Plant-based Biologics and Expression Systems: Partnerships and Collaborations
7.1.1. Analysis by Cumulative Year-wise Trend of Partnerships
7.1.2. Analysis by Type of Partnership
7.1.3. Analysis by Year and Type of Partnership
7.1.4. Analysis by Type of Biologic
7.1.5. Analysis by Type of Partnership and Type of Biologic
7.1.6. Key Players: Analysis by Number of Partnerships
7.1.7. Analysis by Partner Headquarters (Region)
7.1.8. Analysis by Region and Type of Agreement
7.1.9. Intercontinental and Intracontinental Partnerships
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Plant-based Expression System Providers: Company Competitiveness Analysis
8.1.1. Assumptions and Key Parameters
8.1.2. Methodology
8.3. Benchmarking of Portfolio Strength
8.4. Benchmarking of Partnership Strength
8.5. Company Competitiveness Analysis: Small Companies
8.6. Company Competitiveness Analysis: Mid-sized Companies
8.7. Company Competitiveness Analysis: Large Companies
9. PUBLICATIONS ANALYSIS
9.1. Plant-based Biologics and Expression Systems: Publications Analysis
9.1.1. Analysis Methodology
9.1.2. Key Parameters
9.2. Analysis by Year of Publication
9.3. Analysis by Type of Publication
9.4. Key Journals based on Publications Count
9.5. Analysis by Primary Author
9.6. Analysis by Publisher
9.7. Analysis by Primary Funding Body
9.8. Analysis by Journal Impact Factor
9.9. Analysis by Key Journals and Journal Impact Factor
9.10. Word Cloud: Emerging Focus Area
9.11. Timeline Analysis
9.11.1. Analysis by Article Type and Timeline of Receipt, Acceptance and ApprovalAnalysis by Article Type and Timeline of Receipt, Acceptance and Approval
9.11.2. Analysis by Journal Impact Factor and Timeline of Receipt, Acceptance and ApprovalAnalysis by Journal Impact Factor and Timeline of Receipt, Acceptance and Approval
9.11.3. Analysis by Grant Awarded and Timeline of Receipt, Acceptance and Approval
9.12. Benchmarking Methodology
9.13. Benchmarking Analysis
9.14. List of Top 50 Publications
10. PLANT-BASED EXPRESSION SYSTEMS: MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Methodology and Key Assumptions
10.2. Segments Forecasted
10.3. Plant-based Expression Systems: Sales Forecast
10.4. Analysis by Type of Product: Global Sales Forecast, 2022 and 2035
10.4.1. Plant-based Expression Systems Market for Biosimilars, 2022-2035
10.4.2. Plant-based Expression Systems Market for Cell Therapies, 2022-2035
10.4.3. Plant-based Expression Systems Market for Gene Therapies, 2022-2035
10.4.4. Plant-based Expression Systems Market for Monoclonal Antibodies, 2022-2035
10.4.5. Plant-based Expression Systems Market for Vaccines, 2022-2035
10.4.6. Plant-based Expression Systems Market for Others, 2022-2035
10.5. Distribution by Type of Plant: Global Sales Forecast, 2022 and 2035
10.5.1. Plant-based Expression Systems Market for Algae, 2022-2035
10.5.2. Plant-based Expression Systems Market for Barley, 2022-2035
10.5.3. Plant-based Expression Systems Market for Benth, 2022-2035
10.5.4. Plant-based Expression Systems Market for Duckweed, 2022-2035
10.5.5. Plant-based Expression Systems Market for Lettuce, 2022-2035
10.5.6. Plant-based Expression Systems Market for Maize, 2022-2035
10.5.7. Plant-based Expression Systems Market for Moss, 2022-2035
10.5.8. Plant-based Expression Systems Market for Rice, 2022-2035
10.5.9. Plant-based Expression Systems Market for Tomato, 2022-2035
10.5.10. Plant-based Expression Systems Market for Tobacco, 2022-2035
10.5.11. Plant-based Expression Systems Market for Wheat Germ, 2022-2035
10.6. Analysis by Type of Expression System: Global Sales Forecast, 2022 and 2035
10.6.1. Plant-based Expression Systems Market for Stable Expression System, 2022-2035
10.6.2. Plant-based Expression Systems Market for Transient Expression System,2022-2035
10.7. Analysis by Region: Global Sales Forecast, 2022 and 2035
10.7.1. Plant-based Expression Systems Market in North America, 2022-2035
10.7.2. Plant-based Expression Systems Market in Europe, 2022-2035
10.7.3. Plant-based Expression Systems Market in Asia, 2022-2035
10.7.4. Plant-based Expression Systems Market in Latin America, 2022-2035
10.7.5. Plant-based Expression Systems Market in MENA, 2022-2035
10.7.6. Plant-based Expression Systems Market in Rest of the World, 2022-2035
11. PLANT-BASED BIOLOGICS: MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. List of Forecasted DrugsKey Parameters and Assumptions
11.2. List of Forecasted DrugsAnalysis Methodology
11.3. List of Forecasted Drugs
11.3.1. Elelyso, Protalix Biotherapeutics
11.3.1.1. Global Sales Forecast
11.3.1.2. Regional Sales Forecast
11.3.1.3. Net Present Value
11.3.1.4. Value Creation Analysis
11.3.2. PALFORZIA, Aimmune Therapeutics
11.3.2.1. Global Sales Forecast
11.3.2.2. Regional Sales Forecast
11.3.2.3. Net Present Value
11.3.2.4. Value Creation Analysis
11.3.3. OsrHSA, Healthgen Biotechnology
11.3.3.1. Global Sales Forecast
11.3.3.2. Regional Sales Forecast
11.3.3.3. Net Present Value
11.3.3.4. Value Creation Analysis
11.3.4. PRX-102, Protalix Biotherapeutics
11.3.4.1. Global Sales Forecast
11.3.4.2. Regional Sales Forecast
11.3.4.3. Net Present Value
11.3.4.4. Value Creation Analysis
11.3.5. Unnamed_1, Medicago
11.3.5.1. Global Sales Forecast
11.3.5.2. Regional Sales Forecast
11.3.5.3. Net Present Value
11.3.5.4. Value Creation Analysis
11.3.6. Unnamed_2, Medicago
11.3.6.1. Global Sales Forecast
11.3.6.2. Regional Sales Forecast
11.3.6.3. Net Present Value
11.3.7.4. Value Creation Analysis
11.3.7. PRX-110, Protalix Biotherapeutics
11.3.7.1. Global Sales Forecast
11.3.7.2. Regional Sales Forecast
11.3.7.3. Net Present Value
11.3.7.4. Value Creation Analysis
11.3.8. ZMapp, Mapp Biopharmaceutical
11.3.8.1. Global Sales Forecast
11.3.8.2. Regional Sales Forecast
11.3.8.3. Net Present Value
11.3.8.4. Value Creation Analysis
11.4. Global Plant-based Biologics Market: Analysis by Target Disease Indication, 2022 and 2035
11.4.1. Plant-based Biologics Market for Cirrhotic Ascites, 2022-2035
11.4.2. Plant-based Biologics Market for COVID-19, 2022-2035
11.4.3 Plant-based Biologics Market for Cystic Fibrosis, 2022-2035
11.4.4 Plant-based Biologics Market for Ebola Virus Infection, 2022-2035
11.4.5. Plant-based Biologics Market for Fabry Disease, 2022-2035
11.4.6. Plant-based Biologics Market for Gaucher Disease, 2022-2035
11.4.7. Plant-based Biologics Market for Influenza, 2022-2035
11.4.8. Plant-based Biologics Market for Liver Cirrhosis, 2022-2035
11.4.9. Plant-based Biologics Market for Peanut Allergy, 2022-2035
11.5. Plant-based Biologics Market: Analysis by Therapeutic Area, 2022 and 2035
11.5.1. Plant-based Biologics Market for Genetic Disorders, 2022-2035
11.5.2 Plant-based Biologics Market for Infectious Disorders, 2022-2035
11.5.3 Plant-based Biologics Market for Liver Disorders, 2022-2035
11.5.4. Plant-based Biologics Market for Respiratory Disorders, 2022-2035
11.5.5. Plant-based Biologics Market for Others, 2022-2035
11.6. Plant-based Biologics Market: Analysis by Region, 2022 and 2035
11.6.1. Plant-based Biologics Market in North America, 2022-2035
11.6.2. Plant-based Biologics Market in Europe, 2022-2035
11.6.3. Plant-based Biologics Market in Asia, 2022-2035
11.6.4. Plant-based Biologics Market in Rest of the World, 2022-2035
11.7. Plant-based Biologics: Overall Market Opportunity, 2022-2035
11.8. Plant-based Biologics: Market Share of Key Players
11.9. Plant-based Biologics: Regional Distribution, 2022,2028 and 2035
11.10. Region-wise Distribution (Bubble Chart Representation)
12. EXECUTIVE INSIGHTS
12.1. Transactiva
12.1.1. Company Snapshot
12.1.2. Interview Transcript: Sara Raccovelli (Researcher)
12.2. ORF Genetics
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Jъlнus B Kristinsson (Chief Project Manager, Business Development & Co-Founder)
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 1: PUBLICATIONS DATA
15. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
